title: PharmGKB summary: peginterferon-α pathway.
authors.affiliation: Departments of aGenetics bBioengineering, Stanford University, Stanford, California cDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
authors.forename: Scott R
authors.initials: SR
authors.lastname: Shuldiner
authors.forename: Li
authors.initials: L
authors.lastname: Gong
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Muir
authors.forename: Russ B
authors.initials: RB
authors.lastname: Altman
authors.forename: Teri E
authors.initials: TE
authors.lastname: Klein
mesh_terms: D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D011092:Polyethylene Glycols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D000095022:Interferon Lambda
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a